Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$0.34.

  • Insight Molecular Diagnostics' EPS (Basic) rose 6530.61% to -$0.34 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.88, marking a year-over-year increase of 4268.29%. This contributed to the annual value of -$4.67 for FY2024, which is 112111.54% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' EPS (Basic) is -$0.34, which was up 6530.61% from -$0.3 recorded in Q2 2025.
  • Insight Molecular Diagnostics' EPS (Basic)'s 5-year high stood at $0.0 during Q1 2023, with a 5-year trough of -$8.16 in Q4 2022.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.38 (2021), whereas its average is -$1.11.
  • Its EPS (Basic) has fluctuated over the past 5 years, first skyrocketed by 10073.7% in 2023, then tumbled by 13752682.18% in 2024.
  • Insight Molecular Diagnostics' EPS (Basic) (Quarter) stood at -$0.4 in 2021, then tumbled by 1939.89% to -$8.16 in 2022, then skyrocketed by 90.07% to -$0.81 in 2023, then plummeted by 217.63% to -$2.57 in 2024, then skyrocketed by 86.78% to -$0.34 in 2025.
  • Its EPS (Basic) stands at -$0.34 for Q3 2025, versus -$0.3 for Q2 2025 and -$0.26 for Q1 2025.